AbRegen Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 1

AbRegen General Information

Description

Developer of antibody-based therapeutics designed to promote tissue repair by targeting cellular mechanisms involved in wound healing and regeneration. The company develops flii antibody technology that targets negative regulators of wound healing, enabling healthcare providers to improve recovery outcomes for patients with non-healing chronic wounds, cancer, and dermatological conditions.

Contact Information

Website
www.abregen.com.au
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Future Industries Institute
  • University of South Australia
  • Mawson Lakes, South Australia 5095
  • Australia
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • Future Industries Institute
  • University of South Australia
  • Mawson Lakes, South Australia 5095
  • Australia

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbRegen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Later Stage VC 01-Feb-2021 Completed Generating Revenue
To view AbRegen’s complete valuation and funding history, request access »

AbRegen Patents

  • 12

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

AbRegen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018903891-A0 Methods and compositions for the treatment of mucosal lesions Inactive 15-Oct-2018
WO-2020077397-A1 Methods and compositions for the treatment of mucosal lesions Inactive 15-Oct-2018
AU-2014903677-A0 Treating and/or preventing psoriasis Inactive 15-Sep-2014
WO-2016040987-A1 Treating and/or preventing psoriasis Inactive 15-Sep-2014
AU-2012905692-A0 Inhibition of cancer growth and metastasis Inactive 24-Dec-2012
To view AbRegen’s complete patent history, request access »

AbRegen Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
UniSA Ventures University Minority
To view AbRegen’s complete investors history, request access »

Ready to get started?

Request a free trial

AbRegen FAQs

  • When was AbRegen founded?

    AbRegen was founded in 2008.

  • Where is AbRegen headquartered?

    AbRegen is headquartered in Mawson Lakes, Australia.

  • What industry is AbRegen in?

    AbRegen’s primary industry is Biotechnology.

  • Is AbRegen a private or public company?

    AbRegen is a Private company.

  • What is AbRegen’s current revenue?

    The current revenue for AbRegen is .

  • Who are AbRegen’s investors?

    UniSA Ventures has invested in AbRegen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process